An interventional study of Artificial Intelligence system in Esophageal Cancer Stage and Early Esophageal Cancer, sponsored by Fujian Provincial Hospital. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Fujian Provincial Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.
Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 109th largest by planned enrollment of the 394 interventional ones that give a count, is one of 56 that started in 2025, is one of 90 with no phase, reaches primary completion later than 187 of the 237 other live ones, and was the 460th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Sanofi · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
502 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 189 · Phase 3 69 · Phase 4 8
First in 1995; this study’s year is marked. 56 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 80 across the 394 interventional studies, 300 across the 108 observational. Of the 120 that completed or were terminated, 7 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 502 have an industry lead sponsor. The 10 most frequent:
Fujian Provincial Hospital is the lead sponsor of 41 studies on the registry; 23 are open to participants now.
Fujian Provincial Hospital has 1 study filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
61 of the studies in Esophageal Neoplasms with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04513808Phase 3The Cleveland ClinicTotal Intravenous Anesthesia and Recurrence Free Survival | 2026-12 |
| NCT04415853Phase 3Sunshine Lake Pharma Co., Ltd.Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | 2027-08 |
| NCT07303231Phase 3Fujian Medical University Union HospitalThe Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy | 2027-08-01 |
| NCT05252078Jiangxi Provincial Cancer HospitalAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | 2026-11 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 61 to your calendar (.ics) → With an account.
Among the 502 studies in Esophageal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study mainly uses an artificial intelligence system to assist in the classification of the depth of invasion of early esophageal squamous cell carcinoma under ultrasound endoscopy, providing a basis for preoperative T staging and diagnosis and treatment decisions.
For patients with early esophageal squamous cell carcinoma and precancerous lesions who met the inclusion and exclusion criteria and voluntarily participated in this project, they were randomly divided into the AI group and the conventional group by central randomization, with 100 cases in each group(anticipated). Randomization method: The personnel responsible for randomization at the center (who do not participate in the inclusion of subjects) log in to the central randomization system to obtain a randomization number, and finally form a randomization allocation table. Blinding implementation: The observation group and control group determined on the random allocation table were marked as A and B respectively, and then the operating physician implemented protocol A or B. Main indicators: Grading judgment of infiltration depth, pathological consistency
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use artificial intelligence to assist in the determination of the invasion depth of early esophageal squamous cell carcinoma under endoscopic ultrasound
Device: Artificial Intelligence system
Routine diagnosis
Use artificial intelligence to assist in the determination of the invasion depth of early esophageal squamous cell carcinoma under endoscopic ultrasound
Also known as: Artificial Intelligence
The accuracy of grading judgment of infiltration depth
By comparing with the postoperative pathology, the accuracy of the preoperative T grading with the assistance of the artificial intelligence grading system was verified
Time frame: 2 years
survival rate
3-year survival rate
Time frame: Three years
Progression Free-Survival
The period from the start of treatment to tumor progression or death for any reason
Time frame: 1 year
Plan to share: No — It involves the protection of patent technology
No publications or documents are linked to this record.
Start is estimated for Nov 2025; primary completion for Oct 2027, 23 months later.
Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 23 months is below that.
Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fujian Provincial Hospital